201 related articles for article (PubMed ID: 27380459)
21. New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population.
Malagón M; Ramió-Pujol S; Serrano M; Amoedo J; Oliver L; Bahí A; Miquel-Cusachs JO; Ramirez M; Queralt-Moles X; Gilabert P; Saló J; Guardiola J; Piñol V; Serra-Pagès M; Castells A; Aldeguer X; Garcia-Gil LJ
PLoS One; 2020; 15(12):e0243158. PubMed ID: 33259546
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic accuracy of faecal immunochemical test for screening individuals with a family history of colorectal cancer.
Ng SC; Ching JY; Chan V; Wong MC; Suen BY; Hirai HW; Lam TY; Lau JY; Ng SS; Wu JC; Chan FK; Sung JJ
Aliment Pharmacol Ther; 2013 Oct; 38(7):835-41. PubMed ID: 23957462
[TBL] [Abstract][Full Text] [Related]
23. Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels.
Toes-Zoutendijk E; van Leerdam ME; Dekker E; van Hees F; Penning C; Nagtegaal I; van der Meulen MP; van Vuuren AJ; Kuipers EJ; Bonfrer JMG; Biermann K; Thomeer MGJ; van Veldhuizen H; Kroep S; van Ballegooijen M; Meijer GA; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I;
Gastroenterology; 2017 Mar; 152(4):767-775.e2. PubMed ID: 27890769
[TBL] [Abstract][Full Text] [Related]
24. Identifying the optimal strategy for screening of advanced colorectal neoplasia.
Jung YS; Park CH; Kim NH; Park JH; Park DI; Sohn CI
J Gastroenterol Hepatol; 2017 May; 32(5):1003-1010. PubMed ID: 28449340
[TBL] [Abstract][Full Text] [Related]
25. [Screening for colorectal cancer in Italy, 2010 survey].
Zorzi M; Fedato C; Grazzini G; Sassoli de' Bianchi P; Naldoni C; Pendenza M; Sassatelli R; Senore C; Visioli CB; Zappa M
Epidemiol Prev; 2012; 36(6 Suppl 1):55-77. PubMed ID: 23293271
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with false-positive fecal immunochemical tests in a large German colorectal cancer screening study.
Amitay EL; Cuk K; Niedermaier T; Weigl K; Brenner H
Int J Cancer; 2019 May; 144(10):2419-2427. PubMed ID: 30411799
[TBL] [Abstract][Full Text] [Related]
27. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening.
Quintero E; Castells A; Bujanda L; Cubiella J; Salas D; Lanas Á; Andreu M; Carballo F; Morillas JD; Hernández C; Jover R; Montalvo I; Arenas J; Laredo E; Hernández V; Iglesias F; Cid E; Zubizarreta R; Sala T; Ponce M; Andrés M; Teruel G; Peris A; Roncales MP; Polo-Tomás M; Bessa X; Ferrer-Armengou O; Grau J; Serradesanferm A; Ono A; Cruzado J; Pérez-Riquelme F; Alonso-Abreu I; de la Vega-Prieto M; Reyes-Melian JM; Cacho G; Díaz-Tasende J; Herreros-de-Tejada A; Poves C; Santander C; González-Navarro A;
N Engl J Med; 2012 Feb; 366(8):697-706. PubMed ID: 22356323
[TBL] [Abstract][Full Text] [Related]
28. Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy).
Zorzi M; Senore C; Da Re F; Barca A; Bonelli LA; Cannizzaro R; Fasoli R; Di Furia L; Di Giulio E; Mantellini P; Naldoni C; Sassatelli R; Rex D; Hassan C; Zappa M;
Gut; 2015 Sep; 64(9):1389-96. PubMed ID: 25227521
[TBL] [Abstract][Full Text] [Related]
29. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.
Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A;
Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264
[TBL] [Abstract][Full Text] [Related]
30. Fecal hemoglobin concentration is useful for risk stratification of advanced colorectal neoplasia.
Kim NH; Kwon MJ; Kim HY; Lee T; Jeong SH; Park DI; Choi K; Jung YS
Dig Liver Dis; 2016 Jun; 48(6):667-72. PubMed ID: 27012445
[TBL] [Abstract][Full Text] [Related]
31. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas.
Khalid-de Bakker CA; Jonkers DM; Sanduleanu S; de Bruïne AP; Meijer GA; Janssen JB; van Engeland M; Stockbrügger RW; Masclee AA
Cancer Prev Res (Phila); 2011 Oct; 4(10):1563-71. PubMed ID: 21750209
[TBL] [Abstract][Full Text] [Related]
32. First-degree relatives of colorectal cancer patients are likely to show advanced colorectal neoplasia despite a negative fecal immunochemical test.
Cha JM; Lee JI; Joo KR; Shin HP; Park JJ; Jeun JW; Lim JU
Digestion; 2012; 86(4):283-7. PubMed ID: 23051697
[TBL] [Abstract][Full Text] [Related]
33. Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test.
Chiu HM; Lee YC; Tu CH; Chen CC; Tseng PH; Liang JT; Shun CT; Lin JT; Wu MS
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):832-8.e1-2. PubMed ID: 23376002
[TBL] [Abstract][Full Text] [Related]
34. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
35. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity and Specificity of Community Fecal Immunotesting Screening for Colorectal Carcinoma in a High-Risk Canadian Population.
Crouse AL; De Koning L; Sadrzadeh SM; Naugler C
Arch Pathol Lab Med; 2015 Nov; 139(11):1441-5. PubMed ID: 26516941
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of adenomas detected by fecal immunochemical test in colorectal cancer screening.
Cubiella J; Castro I; Hernandez V; González-Mao C; Rivera C; Iglesias F; Cid L; Soto S; de-Castro L; Vega P; Hermo JA; Macenlle R; Martínez A; Martínez-Ares D; Estevez P; Cid E; Herreros-Villanueva M; Portillo I; Bujanda L; Fernández-Seara J;
Cancer Epidemiol Biomarkers Prev; 2014 Sep; 23(9):1884-92. PubMed ID: 24962836
[TBL] [Abstract][Full Text] [Related]
38. Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance.
Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Joo KR; Lee JI
J Clin Gastroenterol; 2017 Oct; 51(9):825-830. PubMed ID: 27824639
[TBL] [Abstract][Full Text] [Related]
39. Multitarget stool DNA testing for colorectal-cancer screening.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Levin TR; Lavin P; Lidgard GP; Ahlquist DA; Berger BM
N Engl J Med; 2014 Apr; 370(14):1287-97. PubMed ID: 24645800
[TBL] [Abstract][Full Text] [Related]
40. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
